Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Kepivance Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The Kepivance market is poised for significant growth, driven by various factors influencing both current and future healthcare landscapes. Historically, the demand for Kepivance, used to treat oral mucositis in cancer patients undergoing chemotherapy, has been fueled by high incidences of the condition, along with limited effective preventive options. Hospital adoption of supportive care drugs and the expansion of bone marrow transplantation have further propelled its growth, supported by the clinical validation of keratinocyte growth factor (KGF) therapy.
Forecasts indicate continued growth, attributed to rising cancer treatment volumes and increased focus on patient quality of life. The expansion of hematopoietic stem cell transplants and advancements in epithelial regeneration therapies are notable trends. A significant increase in healthcare expenditures towards supportive oncology care is expected to boost Kepivance's market share. The American Cancer Society highlighted a rise in cancer cases, from 1,958,310 in 2023 to 2,001,140 in 2024, setting a precedent for increased demand for effective treatments like Kepivance.
The expansion of healthcare infrastructure plays a critical role in the market's growth trajectory. Increased healthcare infrastructure, with substantial investment in specialized facilities, supports the administration of Kepivance. According to a report by Sports Medical, UK hospital construction dominated health projects with a 9% year-on-year increase, totaling $2.61 billion in 2024. These developments are expected to facilitate better delivery and monitoring of Kepivance during cancer therapy.
Another significant driver is the surge in personalized medicine, which aims to tailor treatment to individual patient characteristics. This approach is gaining traction due to advancements in genomics and targeted therapies, enhancing the utilization of Kepivance for chemotherapy and stem cell transplants. The Personalized Medicine Coalition reported a notable increase in FDA-approved personalized treatments, from six in 2022 to 16 in 2023, underscoring the trend's impact on the Kepivance market.
Biovitrum AB is a key player in the Kepivance market. Regionally, North America held the largest market share in 2025, with Asia-Pacific anticipated to experience the fastest growth. The market spans multiple regions, including Asia-Pacific, Europe, North America, South America, the Middle East, and Africa. Countries in the scope of the market include Australia, India, China, South Korea, Japan, the UK, France, Germany, the USA, and Canada.
Trade tariffs have impacted the market by increasing inputs' costs for recombinant protein production and sterile injectable packaging, affecting primarily North American and European oncology centers. However, they are also encouraging local biologics manufacturing, thereby strengthening regional supply chains.
The Kepivance market research report offers comprehensive insights into market statistics, including global market size, regional shares, and competitor analysis. This report enables stakeholders to thrive through detailed segmentation and trend analysis. Kepivance (palifermin) functions predominantly to prevent and treat oral mucositis, employing recombinant human KGF to reduce symptoms in patients undergoing intensive cancer treatments. Available in injectable formulations, it is distributed across various channels, contributing significantly to improving the quality of life for cancer patients.
Global Kepivance Market Trends and Strategies
- Rising Focus on Supportive Oncology Care
- Growth in Stem Cell Transplant Procedures
- Increased Management of Treatment Induced Mucositis
- Preference for Preventive Mucositis Therapies
- Integration of Growth Factors in Oncology Protocols
- Biotechnology, Genomics & Precision Medicine
- Artificial Intelligence & Autonomous Intelligence
- Industry 4.0 & Intelligent Manufacturing
- Digitalization, Cloud, Big Data & Cybersecurity
- Sustainability, Climate Tech & Circular Economy
Report Scope
- Indication: Prevention and Treatment of Oral Mucositis
- Formulation: Injectable, Lyophilized Powder
- Administration: Intramuscular, Subcutaneous
- Distribution: Direct, Wholesalers, Retail and Online Pharmacies
- End-User: Hospitals, Oncology and Hematology Centers, Home Healthcare
For more information about this report visit https://www.researchandmarkets.com/r/xrihai
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
